Working… Menu
Trial record 1 of 4 for:    TXA Burn
Previous Study | Return to List | Next Study

TXA Study in Major Burn Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02753816
Recruitment Status : Terminated (Study enrollment and goals unable to be reached.)
First Posted : April 28, 2016
Last Update Posted : January 7, 2020
Information provided by (Responsible Party):
Spectrum Health Hospitals

Brief Summary:

Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding. Over the past 20 years, it has been used and studied in patients undergoing open-heart surgery, liver transplantation, and urologic surgery. Investigators believe tranexamic acid may possibly decrease bleeding related to major burn surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your stay.

In this study, prior to each surgical procedure to treat the participants burn injury, the participant will receive either the drug tranexamic acid or placebo. The placebo is a liquid that looks like the tranexamic acid medicine, but does not have any active ingredient in it. In this study, both the tranexamic acid and the placebo are considered research.

Condition or disease Intervention/treatment Phase
Tranexamic Acid Burn Major Surgery Drug: Tranexamic Acid Drug: Placebo Comparator Not Applicable

Detailed Description:

Neither the participant nor the study doctor will choose what treatment the participant gets. The participant will have an equal chance of being given the tranexamic acid or the placebo. Neither the participant nor the study doctor will know which treatment the participant is receiving.

The participant will receive one 1 gram dose of either tranexamic acid or placebo immediately before surgery. The dose of tranexamic acid or placebo will be given in the participants vein over a 10-minute period.

Information from the participants medical record related to their surgery and recovery time in the hospital will be collected by medical staff assisting with this study and recorded on study forms. These study forms will be labeled with the participants study number instead of their name.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial
Study Start Date : April 2016
Actual Primary Completion Date : December 3, 2019
Actual Study Completion Date : December 3, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tranexamic Acid
1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
Drug: Tranexamic Acid
Placebo Comparator: Placebo
Placebo given over 10 minutes into the vein once prior to surgery
Drug: Placebo Comparator

Primary Outcome Measures :
  1. Intraoperative Blood Loss as Measured by Pre and Post Procedure Hemoglobin levels (g/dl) [ Time Frame: From time of surgery to 30 days post hospital discharge ]
    To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries.

  2. Post Operative Transfusion Rates as Determined by Hemoglobin Levels of < 7.0 g/dl or <10.0 g/dl with clinical symptomology [ Time Frame: From time of surgery to 30 days post hospital discharge ]
    To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries.

Secondary Outcome Measures :
  1. Effect of Tranexamic Acid on the Total Length of Hospital Admission for a Large (350 cm2) Burn Injury [ Time Frame: From time of surgery to 30 days post hospital discharge ]
    To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects undergoing burn excision surgery for standard of care purposes (to include: greater than or equal to 350 cm2 of full thickness or deep partial thickness burns)
  • Male or female > 18 years of age
  • Subject or subject's medical decision maker agrees to participate in this study and provides informed consent

Exclusion Criteria:

  • Subjects with a history of hypercoagulopathy, deep vein thrombosis (DVT), pulmonary embolism
  • Baseline creatinine level greater than 2.83 mg/dL
  • Subjects with known hypersensitivity to tranexamic acid
  • Patients with acquired defective color vision
  • Patients with subarachnoid hemorrhage
  • Children
  • Pregnant women
  • Prisoners

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02753816

Layout table for location information
United States, Michigan
Spectrum Health Hospital
Grand Rapids, Michigan, United States, 49503
Sponsors and Collaborators
Spectrum Health Hospitals
Layout table for investigator information
Principal Investigator: Elizabeth Steensma, MD Spectrum Health Hospitals
Muller M, Gahankari D, Herndon DN. Operative wound management. Total burn care. 2007;3:177-195.
Jennes S, Degrave E, Despiegeleer X, Grenez O. Effect of tranexamic acid on blood loss in burn surgery: A preliminary study: 33. Journal of Burn Care & Research. 2003;24:S59.
Twisk JWR. Applied Multilevel Analysis: A Practical Guide for Medical Researchers. 2006. Cambridge University Press, London, UK.
American Burn Association. Burn incidence fact sheet. Accessed May 20, 2015.

Layout table for additonal information
Responsible Party: Spectrum Health Hospitals Identifier: NCT02753816    
Other Study ID Numbers: 2015-154
First Posted: April 28, 2016    Key Record Dates
Last Update Posted: January 7, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Spectrum Health Hospitals:
Tranexamic Acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action